Hannah Clarke

The assay is designed to detect multiple cancers, including prostate, bladder, and kidney cancer, through a simple, non-invasive urine sample.

In this interview, Brett Trockman, MD, FACS, details how shifting guideline recommendations and expanding treatment options are allowing for more personalized approaches to sacral neuromodulation.

Treatment with 177Lu-PSMA-617 may durably delay disease progression compared with deferred ADT in men with oligometastatic hormone-sensitive prostate cancer.

Investigators in the BioFront trial are evaluating whether CBM588 enhances the efficacy of immune checkpoint inhibitors in renal cell carcinoma.

Use of virtual reality for patient education before shock wave lithotripsy led to improved patient understanding and reduced anxiety.

The findings highlight the potential of field-effect-informed liquid biopsy methods to guide adjuvant treatment decisions in NMIBC.

ImmunityBio has submitted a formal response to the FDA and initiated corrective actions.

The following FAQ highlights key recommendations for urologists from the 2026 AUA Vasectomy Guideline.

The code, J9183, may be used by physicians and treatment centers for billing and reimbursement beginning April 1, 2026.

A recap of the FDA submissions and regulatory decisions in urology from March 2026.

The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH.

Take a look through the top 10 stories in urology from the past quarter.

A recap of the FDA approvals and clearances across urology from January through March.

The device will be available over the counter in the US, with anticipated availability beginning in April 2026.

At 3 years, transdermal estradiol demonstrated noninferior MFS compared with standard LHRH agonists.

The study is evaluating the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with locally advanced or metastatic castration-resistant prostate cancer.

The system can be used as an irrigation option for ureteroscopy, cystoscopy, percutaneous nephrolithotomy, and benign prostatic hyperplasia procedures.

A comprehensive guide to the key regulatory decisions and conferences slated for April-June of 2026.

The company remains on track to submit a supplemental Biologics License Application in the fourth quarter of 2026.

The 5-factor model aims to refine treatment decision-making by stratifying patients into 3 clinically actionable subgroups.

The label update permits thawing of nadofaragene in a 25 °C water bath over approximately 25 minutes.

Findings from a systematic review suggest that increased fluid intake, dietary modification, and selected pharmacologic therapies may reduce recurrence of kidney stones in adults.

The European Commission is expected to have a final decision on the application in the second quarter of 2026.

Two new analyses from the ASPIRE trial showed lower health care consumption events and reduced follow-up costs with the SURE procedure vs URS, with RSV emerging as a key predictor of long-term utilization.

The results highlight the complexity of secondary prevention in stone disease.

The NCCN now assigns a Category 2A recommendation for nadofaragene in patients with high-risk BCG-unresponsive NMIBC with papillary tumors without CIS.

Topline results from the TALAPRO-3 study showed that adding talazoparib to enzalutamide improved rPFS for patients with HRR-mutated mCSPC.